Table 1.
Baseline characteristics of the evaluable population.
| Characteristic | N = 57 |
|---|---|
| Age, mean (SD) | 59.2 (9.4) |
| Body fat %, mean (SD) | 43.4 (8.0) |
| BMI (kg/m2), mean (SD) | 32.6 (13.2) |
| BMI category | |
| Normal | 8 (14) |
| Overweight | 19 (33) |
| Obese | 30 (53) |
| Steps per day, mean (SD) | 6642 (2817) |
| Steps per day category | |
| <5,000 | 16 (28) |
| 5,000–9,999 | 35 (61) |
| ≥10,000 | 6 (11) |
| Race | |
| Non-Hispanic white | 33 (58) |
| Black | 16 (28) |
| Hispanic white | 1 (2) |
| Asian | 0 (0) |
| Other | 7 (12) |
| Education | |
| High school | 2 (4) |
| Some college | 16 (28) |
| College degree | 26 (46) |
| Graduate degree | 13 (23) |
| Income | |
| Not enough to be comfortable | 5 (9) |
| Comfortable | 35 (61) |
| More than comfortable | 16 (28) |
| No answer | 1 (2) |
| Employment status | |
| Part-time | 8 (14) |
| Full-time | 27 (47) |
| Retired | 15 (26) |
| Disabled | 1 (2) |
| Other | 6 (11) |
| Time since diagnosis, months | |
| Mean (SD) | 63.7 (58.6) |
| Stage | |
| In-situ | 2 (4) |
| I | 30 (53) |
| II | 18 (32) |
| III | 7 (12) |
| Breast cancer subtype | |
| ER+/HER2− | 32 (56) |
| ER+/HER2+ | 6 (11) |
| ER−/HER2+ | 2 (4) |
| ER−/HER2− | 17 (30) |
| Treatment | |
| Surgery | 57 (100) |
| Radiation | 38 (67) |
| Chemotherapy | 33 (58) |
| HER2 targeted therapy | 8 (14) |
| Anti-estrogen therapy | 37 (65) |
All data presented as No. (%) unless otherwise indicated.
BMI, body mass index; SD, standard deviation.